

Stuart J Connolly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11657861/publications.pdf>

Version: 2024-02-01

398
papers

70,255
citations

1046

113
h-index

625

258
g-index

401
all docs

401
docs citations

401
times ranked

30739
citing authors

#	ARTICLE	IF	CITATIONS
1	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	3.8	8
2	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	3.0	8
3	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	3.0	11
4	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	3.8	18
5	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. <i>Stroke</i> , 2022, 53, 45-52.	2.0	8
6	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2022, 53, 532-543.	2.0	25
7	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
8	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. <i>Thrombosis and Haemostasis</i> , 2022, 122, 998-1005.	3.4	19
9	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. <i>Europace</i> , 2022, , .	1.7	13
10	Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12655.	0.7	10
11	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
12	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1434-1441.	1.7	2
13	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. <i>Critical Care</i> , 2022, 26, .	5.8	23
14	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
15	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	2.2	7
16	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	3.8	15
17	Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153%152 middle-aged individuals. <i>Cardiovascular Research</i> , 2021, 117, 1523-1531.	3.8	33
18	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021, 121, 518-528.	3.4	8

#	ARTICLE	IF	CITATIONS
19	Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2021, 78, 11.	9.0	28
20	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.7	11
21	Semi-automatic measurement of intracranial hemorrhage growth on non-contrast CT. <i>International Journal of Stroke</i> , 2021, 16, 192-199.	5.9	6
22	High-Sensitivity Estimate of the Incidence of New-Onset Atrial Fibrillation in Critically Ill Patients. , 2021, 3, e0311.		9
23	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	3.4	14
24	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Circulation</i> , 2021, 143, 1863-1873.	1.6	28
25	Screening for Atrial Fibrillation in the Older Population. <i>JAMA Cardiology</i> , 2021, 6, 558.	6.1	101
26	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	2.9	6
27	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. <i>Canadian Journal of Cardiology</i> , 2021, 37, 803-809.	1.7	6
28	Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2875-2886.	2.8	35
29	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	2.0	25
30	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. <i>New England Journal of Medicine</i> , 2021, 384, 2081-2091.	27.0	321
31	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	2.8	31
32	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the <i>ADRB1</i> Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009591.	4.8	5
33	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. <i>CJC Open</i> , 2021, 3, 1482-1489.	1.5	9
34	LVS-CHARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a Worldwide Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017735.	3.7	4
35	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab513.	0.9	4
36	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008548.	3.9	11

#	ARTICLE	IF	CITATIONS
37	Dose Limiting, Adverse Event Associated Bradycardia with β -blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. <i>Heart Rhythm O2</i> , 2021, 3, 40-49.	1.7	0
38	Prospective Long-term Follow-up of Silicone-polyurethane - insulated Implantable Cardioverter Defibrillator Leads. <i>Heart Rhythm O2</i> , 2021, 3, 57-64.	1.7	2
39	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. <i>JAMA Neurology</i> , 2020, 77, 43.	9.0	54
40	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	1.8	28
41	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 938-943.	2.0	25
42	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.	1.6	17
43	Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial. <i>CJC Open</i> , 2020, 2, 354-359.	1.5	2
44	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2020, 77, 1233.	9.0	37
45	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008655.	4.8	1
46	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15
47	Permanent Bilateral Carotid Filters for Stroke Prevention in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2020, 22, 144.	2.9	3
48	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	3.7	37
49	Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. <i>Circulation</i> , 2020, 142, 1697-1699.	1.6	16
50	The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <i>American Heart Journal</i> , 2020, 225, 69-77.	2.7	43
51	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	3.8	14
52	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. <i>Stroke</i> , 2020, 51, 2139-2147.	2.0	7
53	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
54	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	1.7	13

#	ARTICLE	IF	CITATIONS
55	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
56	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	2.5	1
57	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020, 51, 1797-1804.	2.0	54
58	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	5.9	11
59	Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. <i>Heart Rhythm</i> , 2019, 16, 83-90.	0.7	1
60	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.	2.0	72
61	Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. <i>European Heart Journal</i> , 2019, 40, 3026-3032.	2.2	13
62	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	1.3	299
63	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	2.8	95
64	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. <i>JACC: Heart Failure</i> , 2019, 7, 586-598.	4.1	22
65	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	1.3	108
66	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
67	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.	2.0	78
68	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.8	30
69	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
70	Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. <i>Circulation</i> , 2019, 139, 757-759.	1.6	3
71	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
72	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2273-2279.	1.6	27

#	ARTICLE	IF	CITATIONS
73	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	2.8	39
74	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2846-2856.	1.6	11
75	Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 389-395.	1.7	33
76	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. <i>Europace</i> , 2019, 21, 1023-1030.	1.7	5
77	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. <i>JAMA Neurology</i> , 2019, 76, 764.	9.0	147
78	Effectiveness of single- vs dual-coil implantable defibrillator leads: An observational analysis from the SIMPLE study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1078-1085.	1.7	5
79	Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 753.	7.4	176
80	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
81	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
82	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2845-2854.	2.8	94
83	Atrial fibrillation detected initially during acute medical illness: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 130-141.	1.0	37
84	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the Atrial Fibrillation Registry (AF Registry). <i>Journal of the American Heart Association</i> , 2019, 8, e010107.	3.7	17
85	Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons. <i>Europace</i> , 2019, 21, 445-450.	1.7	7
86	Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. <i>BMJ Open</i> , 2018, 8, e017765.	1.9	60
87	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018, 34, 295-302.	1.7	25
88	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, T ₁ ETQq0 0 0 rgBT /Oyerlock 10 Tf 50 142	2.2	92
89	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	2.7	14
90	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005795.	3.9	25

#	ARTICLE	IF	CITATIONS
91	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	2.7	9
92	Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. <i>American Heart Journal</i> , 2018, 199, 75-82.	2.7	24
93	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	2.2	72
94	Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). <i>American Heart Journal</i> , 2018, 201, 160-163.	2.7	26
95	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	2.8	296
96	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.	1.6	46
97	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation—the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , 2018, 20, 253-262.	1.7	11
98	Atrial fibrillation occurring transiently with stress. <i>Current Opinion in Cardiology</i> , 2018, 33, 58-65.	1.8	26
99	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
100	Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 2018, 121, 584-589.	1.6	14
101	Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. <i>Heart Rhythm</i> , 2018, 15, 386-392.	0.7	11
102	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	13.7	426
103	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	13.7	651
104	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
105	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology, The</i> , 2018, 17, 1053-1060.	10.2	146
106	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 379, 986-987.	27.0	35
107	Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow-up cohort study. <i>Clinical Cardiology</i> , 2018, 41, 1273-1280.	1.8	13
108	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16

#	ARTICLE	IF	CITATIONS
109	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	27.0	730
110	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	131
111	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. <i>Open Heart</i> , 2018, 5, e000800.	2.3	9
112	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	2.8	56
113	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	2.8	91
114	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet</i> , 2018, 391, 2325-2334.	13.7	236
115	Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation: an analysis from the SIMPLE study. <i>Europace</i> , 2018, 20, 1798-1803.	1.7	0
116	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017, 19, euw116.	1.7	20
117	Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. <i>Europace</i> , 2017, 19, euw221.	1.7	26
118	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 324.	6.1	28
119	Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. <i>Heart Rhythm</i> , 2017, 14, 801-807.	0.7	122
120	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	2.9	78
121	Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2017, 48, 867-872.	2.0	408
122	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	2.7	258
123	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	2.6	3
124	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	2.7	42
125	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	1.7	133
126	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	2.2	428

#	ARTICLE	IF	CITATIONS
127	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	6.1	106
128	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	1.7	16
129	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	27.0	1,745
130	Subclinical Atrial Fibrillation in Older Patients. <i>Circulation</i> , 2017, 136, 1276-1283.	1.6	194
131	Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2633-2635.	2.8	3
132	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	1.4	31
133	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
134	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
135	Apical versus Non-Apical Lead: Is ICD Lead Position Important for Successful Defibrillation?. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 581-586.	1.7	7
136	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol. <i>BMJ Open</i> , 2016, 6, e009364.	1.9	12
137	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	5.5	83
138	Anticoagulant-Related Bleeding and Mortality –. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2522-2524.	2.8	13
139	High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. <i>Open Heart</i> , 2016, 3, e000515.	2.3	38
140	Andexanet Alfa for Factor Xa Inhibitor Reversal. <i>New England Journal of Medicine</i> , 2016, 375, 2498-2500.	27.0	22
141	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016, 387, 2302-2311.	13.7	389
142	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016, 11, 526-533.	5.9	113
143	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
144	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016, 388, 1161-1169.	13.7	216

#	ARTICLE	IF	CITATIONS
145	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
146	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	27.0	692
147	Global Survey of the Frequency of Atrial Fibrillationâ€“Associated Stroke. <i>Stroke</i> , 2016, 47, 2197-2202.	2.0	62
148	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	1.7	29
149	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	1.7	19
150	Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. <i>Heart Rhythm</i> , 2016, 13, 504-510.	0.7	12
151	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	1.6	91
152	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2682.	2.8	1
153	Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS ₂ Score. <i>Circulation Journal</i> , 2015, 79, 2138-2147.	1.6	14
154	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	3.4	201
155	Letter by Longtin et al Regarding Article, â€œRates of and Factors Associated With Infection in 200â€™s Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registryâ€• <i>Circulation</i> , 2015, 131, e517.	1.6	0
156	Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. <i>International Journal of Stroke</i> , 2015, 10, 1031-1036.	5.9	46
157	Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0129282.	2.5	79
158	The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. <i>European Heart Journal</i> , 2015, 36, 1640-1642.	2.2	9
159	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	2.8	197
160	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015, 36, 281-288.	2.2	253
161	Response to Letter Regarding Article â€œTemporal Relationship Between Subclinical Atrial Fibrillation and Embolic Eventsâ€• <i>Circulation</i> , 2015, 131, e337-8.	1.6	0
162	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90

#	ARTICLE	IF	CITATIONS
163	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , 2015, 196, 127-131.	1.7	74
164	Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). <i>Lancet, The</i> , 2015, 385, 785-791.	13.7	214
165	Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. <i>Stroke</i> , 2015, 46, 667-672.	2.0	46
166	Randomized Trial of Benznidazole for Chronic Chagasâ€™ Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015, 373, 1295-1306.	27.0	807
167	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1204-1209.	1.6	54
168	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 1151-1160.	2.7	99
169	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. <i>New England Journal of Medicine</i> , 2015, 373, 2413-2424.	27.0	907
170	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015, 6, 267-277.	1.1	1
171	Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial. <i>Stroke</i> , 2014, 45, 2989-2994.	2.0	15
172	Interaction Between Digoxin and Dronedaronone in the PALLAS Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1019-1025.	4.8	66
173	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial." <i>Circulation</i> , 2014, 130, e107.	1.7	29
174	Prevention of Stroke in Patients With Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2014, 371, 1129-1137.		0
175	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. <i>Europace</i> , 2014, 16, 174-181.	1.7	29
176	An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. <i>Europace</i> , 2014, 16, 1117-1124.	1.7	8
177	Additional Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2014, 371, 1464-1465.	27.0	47
178	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin." <i>Circulation</i> , 2014, 130, e95.	1.6	0
179	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. <i>Heart Rhythm</i> , 2014, 11, 2156-2162.	0.7	28
180	Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2). <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 692.	7.4	533

#	ARTICLE	IF	CITATIONS
181	Patient outcomes using the European label for dabigatran. <i>Thrombosis and Haemostasis</i> , 2014, 112, 933-942.	3.4	94
182	Predictors of early and late stroke following cardiac surgery. <i>Cmaj</i> , 2014, 186, 905-911.	2.0	52
183	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014, 35, 1856-1863.	2.2	28
184	Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. <i>European Heart Journal</i> , 2014, 35, 1831-1833.	2.2	12
185	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	2.8	733
186	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 669-675.	1.6	14
187	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2885-2886.	2.8	5
188	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 435-442.	2.1	10
189	Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. <i>Heart Failure Reviews</i> , 2014, 19, 305-313.	3.9	24
190	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
191	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
192	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	2.2	42
193	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	1.6	324
194	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	2.9	47
195	Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2014, 64, 585-587.	2.8	6
196	Embolic strokes of undetermined source: the case for a new clinical construct. <i>Lancet Neurology</i> , 2014, 13, 429-438.	10.2	1,268
197	Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014, 160, JC4.	3.9	0
198	Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 113-120.	0.3	18

#	ARTICLE	IF	CITATIONS
199	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	27.0	1,201
200	Dabigatran Versus Warfarin. <i>Stroke</i> , 2013, 44, 1891-1896.	2.0	292
201	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
202	Left Atrial Appendage Occlusion Study II (LAAOS II). <i>Canadian Journal of Cardiology</i> , 2013, 29, 1443-1447.	1.7	95
203	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195
204	Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 381-387.	1.7	55
205	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. <i>Circulation</i> , 2013, 127, 634-640.	1.6	447
206	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	2.1	59
207	Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Canadian Journal of Cardiology</i> , 2013, 29, 652-658.	1.7	54
208	Reply to the Editor—Shocks and Mortality versus Pacing and Mortality. <i>Heart Rhythm</i> , 2013, 10, e9-e10.	0.7	0
209	Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 246-252.e5.	4.4	67
210	Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 224-228.	1.7	83
211	Balancing the Benefits and Risks of Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	2.8	59
212	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	2.2	160
213	Atrial fibrillation is associated with increased mortality: causation or association?. <i>European Heart Journal</i> , 2013, 34, 1027-1030.	2.2	40
214	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013, 34, 2752-2759.	2.2	21
215	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial." <i>Circulation</i> , 2013, 127, e506.	1.6	2
216	Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy." <i>Circulation</i> , 2013, 127, e278-9.	1.6	1

#	ARTICLE	IF	CITATIONS
217	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013, 34, 1498-1505.	2.2	109
218	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1053-1061.	7.1	82
219	Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2012, 5, 566-570.	3.9	155
220	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. <i>Circulation</i> , 2012, 126, 2309-2316.	1.6	133
221	Permanent Pacemaker Therapy for Neurally Mediated Syncope. <i>Circulation</i> , 2012, 125, 2552-2553.	1.6	5
222	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	1.6	348
223	Effect of <i>PON1</i> Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 250-256.	5.1	25
224	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	1.6	346
225	Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial". <i>Circulation</i> , 2012, 125, .	1.6	2
226	Relevance of Electrical Remodeling in Human Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 626-631.	4.8	30
227	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians". <i>Stroke</i> , 2012, 43, e46-7; author reply e49.	2.0	0
228	Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 890-923.	1.7	79
229	Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 429-435.	1.6	94
230	Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. <i>Heart Rhythm</i> , 2012, 9, 1241-1246.	0.7	141
231	Reply to the Editor "Electrogram Confirmation of Atrial High-Rate Episodes. <i>Heart Rhythm</i> , 2012, 9, e17-e18.	0.7	0
232	Implantable cardioverter-defibrillator shock prevention does not reduce mortality: A systemic review. <i>Heart Rhythm</i> , 2012, 9, 2068-2074.	0.7	26
233	Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. <i>Stroke</i> , 2012, 43, 1511-1517.	2.0	385
234	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	1.7	37

#	ARTICLE	IF	CITATIONS
235	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	1.4	219
236	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. <i>Stroke</i> , 2012, 43, 3291-3297.	2.0	83
237	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfeTy and pharmacokinetics of oral dabiGatran etexilate in patients after heart valve replacement (RE-ALIGN). <i>American Heart Journal</i> , 2012, 163, 931-937.e1.	2.7	164
238	The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial. <i>Canadian Journal of Cardiology</i> , 2012, 28, 95-101.	1.7	11
239	Age and Mental Health Predict Early Device-Specific Quality of Life in Patients Receiving Prophylactic Implantable Defibrillators. <i>Canadian Journal of Cardiology</i> , 2012, 28, 502-507.	1.7	9
240	Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. <i>Heart Rhythm</i> , 2012, 9, 1667-1673.	0.7	54
241	Subclinical Atrial Fibrillation and the Risk of Stroke. <i>New England Journal of Medicine</i> , 2012, 366, 120-129.	27.0	1,751
242	The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: A randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. <i>American Heart Journal</i> , 2012, 164, 146-152.	2.7	32
243	Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. <i>Heart Rhythm</i> , 2012, 9, 217-224.e2.	0.7	7
244	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	3.4	24
245	Warfarin in Heart Failure. <i>New England Journal of Medicine</i> , 2012, 366, 1936-1938.	27.0	11
246	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
247	Are Elderly Patients at Increased Risk of Complications Following Pacemaker Implantation? A Meta-Analysis of Randomized Trials. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 131-134.	1.2	96
248	Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 462-472.	1.7	10
249	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 225-231.	10.2	164
250	A Randomized-€Controlled Pilot Study Comparing ICD Implantation with and Without Intraoperative Defibrillation Testing in Patients with Heart Failure and Severe Left Ventricular Dysfunction: A Substudy of the RAFT Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1313-1316.	1.7	35
251	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. <i>Circulation</i> , 2011, 124, 2649-2660.	1.6	45
252	Antiarrhythmic Drug Therapy for New-Onset Ventricular Arrhythmia (VT/VF) in ICD Patients. <i>Cardiac Electrophysiology Clinics</i> , 2011, 3, 651-661.	1.7	1

#	ARTICLE	IF	CITATIONS
253	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	27.0	2,207
254	Dronedaronone in High-Risk Permanent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 2268-2276.	27.0	547
255	Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -. <i>Circulation Journal</i> , 2011, 75, 800-805.	1.6	107
256	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS ₂ Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	3.9	181
257	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	3.9	119
258	Effects of Dronedaronone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 770-776.	1.7	14
259	Rhythm- and Rate-Controlling Effects of Dronedaronone in Patients With Atrial Fibrillation (from the Tj ETQq1 1 0.784314 rgBT /Overlook	1.6	57
260	Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 131-136.	1.6	446
261	Irbesartan in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 928-938.	27.0	220
262	Computerized clinical decision support systems for therapeutic drug monitoring and dosing: A decision-maker-researcher partnership systematic review. <i>Implementation Science</i> , 2011, 6, 90.	6.9	76
263	Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. <i>European Heart Journal</i> , 2011, 32, 2347-2349.	2.2	12
264	Impact of dronedaronone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. <i>Europace</i> , 2011, 13, 1118-1126.	1.7	33
265	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
266	Advances in treatment and management. <i>Nature Reviews Cardiology</i> , 2011, 8, 67-68.	13.7	8
267	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 633-641.	3.4	311
268	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology</i> , The, 2010, 9, 1157-1163.	10.2	399
269	Canadian Registry of ICD Implant Testing Procedures (CREDIT): Current Practice, Risks, and Costs of Intraoperative Defibrillation Testing. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 177-182.	1.7	38
270	Explaining the RE-LY Trial. <i>Canadian Journal of Hospital Pharmacy</i> , 2010, 63, 334-6.	0.1	0

#	ARTICLE	IF	CITATIONS
271	Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction. <i>Circulation</i> , 2010, 122, 2645-2652.	1.6	126
272	Dabigatran and Warfarin in Vitamin K Antagonist-“Naive and “Experienced Cohorts With Atrial Fibrillation. <i>Circulation</i> , 2010, 122, 2246-2253.	1.6	158
273	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	2.2	35
274	Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 277-283.	2.2	96
275	Dronedaronone in patients with congestive heart failure: insights from ATHENA. <i>European Heart Journal</i> , 2010, 31, 1717-1721.	2.2	61
276	A rare cause of implantable cardioverter-defibrillator failure: Short-circuiting via an unused pace/sense lead. <i>Heart Rhythm</i> , 2010, 7, 1630-1631.	0.7	3
277	Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). <i>Heart Rhythm</i> , 2010, 7, 1171-1177.	0.7	36
278	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. <i>New England Journal of Medicine</i> , 2010, 363, 1704-1714.	27.0	497
279	Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1796-1802.	2.8	129
280	Dronedaronone for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1353-1354.	2.8	0
281	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010, 125, e128-e131.	1.7	11
282	Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>American Heart Journal</i> , 2010, 159, 348-353.e1.	2.7	146
283	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet</i> , The, 2010, 376, 975-983.	13.7	913
284	Newly Identified Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2010, 363, 1875-1876.	27.0	652
285	Effect of Dronedaronone on Cardiovascular Events in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 668-678.	27.0	1,029
286	Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedaronone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. <i>Circulation</i> , 2009, 120, 1174-1180.	1.6	228
287	Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin. <i>Circulation</i> , 2009, 120, 1927-1932.	1.6	63
288	Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. <i>Heart</i> , 2009, 95, 95-97.	2.9	10

#	ARTICLE	IF	CITATIONS
289	Prevention of Atrial Fibrillation. <i>Circulation</i> , 2009, 119, 606-618.	1.6	446
290	Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 2066-2078.	27.0	1,273
291	Postoperative Low-Molecular-Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	1.2	92
292	A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 138-144.	1.7	111
293	Design and Use of a Quantitative Scale for Measuring Presyncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 888-893.	1.7	12
294	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	27.0	9,839
295	Potential demographic and baseline variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator – A prognostic indicator. <i>International Journal of Cardiology</i> , 2008, 126, 101-107.	1.7	10
296	Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. <i>American Heart Journal</i> , 2008, 155, 829-840.	2.7	18
297	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). <i>American Heart Journal</i> , 2008, 156, 37-43.	2.7	183
298	Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2667-2677.	27.0	1,421
299	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
300	Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. <i>Stroke</i> , 2008, 39, 1482-1486.	2.0	177
301	Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation. , 2008, , 185-195.		1
302	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. <i>Blood</i> , 2008, 112, 33-33.	1.4	20
303	Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. <i>New England Journal of Medicine</i> , 2007, 357, 987-999.	27.0	597
304	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. <i>Circulation</i> , 2007, 116, 449-455.	1.6	82
305	Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. <i>European Heart Journal</i> , 2007, 28, 1746-1749.	2.2	152
306	Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. <i>Journal of Hypertension</i> , 2007, 25, 307-313.	0.5	21

#	ARTICLE	IF	CITATIONS
307	The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: A substudy of the Canadian Trial of Physiological Pacing (CTOPP). <i>Heart Rhythm</i> , 2007, 4, 1024-1028.	0.7	8
308	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2156-2161.	2.8	422
309	Worsening of Symptoms Before Presentation with Vasovagal Syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 954-959.	1.7	17
310	Rationale and Design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedaronone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 19, 071121154351003-???	1.7	51
311	Clinical Trials of Pacing Modes. , 2007, , 337-356.		0
312	Stroke prevention in patients with atrial fibrillation: The diagnosis and management of hypertension by specialists. <i>Canadian Journal of Cardiology</i> , 2006, 22, 485-488.	1.7	9
313	Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. <i>American Heart Journal</i> , 2006, 152, 967-973.	2.7	167
314	Benefits of left atrial appendage occlusion. <i>American Heart Journal</i> , 2006, 151, e3.	2.7	1
315	ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). <i>American Heart Journal</i> , 2006, 152, 442-447.	2.7	117
316	Age of First Faint in Patients with Vasovagal Syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 49-54.	1.7	122
317	Efficacy of Azimilide for the Maintenance of Sinus Rhythm in Patients With Paroxysmal Atrial Fibrillation in the Presence and Absence of Structural Heart Disease. <i>American Journal of Cardiology</i> , 2006, 98, 215-218.	1.6	32
318	Use and Misuse of Surrogate Outcomes in Arrhythmia Trials. <i>Circulation</i> , 2006, 113, 764-766.	1.6	29
319	Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold. <i>Circulation</i> , 2006, 114, 104-109.	1.6	167
320	Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing. <i>Circulation</i> , 2006, 114, 11-17.	1.6	238
321	Comparison of Î²-Blockers, Amiodarone Plus Î²-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators<SUBTITLE>The OPTIC Study: A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 165.	7.4	672
322	Omega-3 fatty acids and sudden arrhythmic death. <i>Herz</i> , 2006, 31 Suppl 3, 59-64.	1.1	0
323	Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction - A combined analysis from multicenter trials. <i>Clinical Cardiology</i> , 2005, 28, 471-478.	1.8	14
324	Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. <i>European Heart Journal</i> , 2005, 26, 1385-1393.	2.2	69

#	ARTICLE	IF	CITATIONS
325	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. <i>Country Review Ukraine</i> , 2005, 7, C28-C33.	0.8	11
326	Cost-effectiveness of physiologic pacing: Results of the Canadian Health Economic Assessment of Physiologic Pacing. <i>Heart Rhythm</i> , 2005, 2, 270-275.	0.7	18
327	Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. <i>American Heart Journal</i> , 2005, 149, 489-496.	2.7	317
328	Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. <i>American Heart Journal</i> , 2005, 150, 288-293.	2.7	436
329	Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1832-1839.	2.8	774
330	Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. <i>Current Opinion in Cardiology</i> , 2005, 20, 31-7.	1.8	47
331	Canadian Trial of Physiological Pacing. <i>Circulation</i> , 2004, 109, 357-362.	1.6	184
332	Role of oral anticoagulation in management of atrial fibrillation. <i>British Heart Journal</i> , 2004, 90, 813-817.	2.1	33
333	Prophylactic Use of an Implantable Cardioverter-Defibrillator after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2004, 351, 2481-2488.	27.0	1,358
334	The management of patients with carotid sinus syndrome: is pacing the answer?. <i>Clinical Autonomic Research</i> , 2004, 14, i80-i86.	2.5	35
335	Atrial fibrillation: guiding lessons from epidemiology. <i>Cardiology Clinics</i> , 2004, 22, 1-8.	2.2	9
336	Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. <i>American Heart Journal</i> , 2004, 147, 837-840.	2.7	107
337	The association of left atrial size and occurrence of atrial fibrillation: A prospective cohort study from the Canadian Registry of Atrial Fibrillation. <i>American Heart Journal</i> , 2004, 148, 649-654.	2.7	98
338	Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 189-192.	1.0	16
339	The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 447-451.	1.0	7
340	Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. <i>American Journal of Cardiology</i> , 2003, 91, 9-14.	1.6	206
341	Combined Antiplatelet Therapy in Atrial Fibrillation:. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S60-S63.	1.7	34
342	Prevention of Vascular Events in Patients with Atrial Fibrillation:. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S52-S55.	1.7	7

#	ARTICLE	IF	CITATIONS
343	Long-term amiodarone therapy and the risk of complications after cardiac surgery: Results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 633-637.	0.8	18
344	Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. <i>American Heart Journal</i> , 2003, 146, 489-493.	2.7	22
345	Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The I ² -Blocker Length Of Stay (BLOS) study. <i>American Heart Journal</i> , 2003, 145, 226-232.	2.7	152
346	Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. <i>American Heart Journal</i> , 2003, 145, 430-437.	2.7	82
347	Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. <i>American Heart Journal</i> , 2003, 145, 174-178.	2.7	72
348	Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts. <i>American Heart Journal</i> , 2003, 145, 418-423.	2.7	32
349	Asymptomatic or "Silent" Atrial Fibrillation. <i>Circulation</i> , 2003, 107, 1141-1145.	1.6	171
350	Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal Syncope. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2224.	7.4	453
351	Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 388-394.	2.0	7
352	Historical criteria that distinguish syncope from seizures. <i>Journal of the American College of Cardiology</i> , 2002, 40, 142-148.	2.8	358
353	Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. <i>American Heart Journal</i> , 2002, 143, 643-649.	2.7	36
354	Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. <i>American Heart Journal</i> , 2002, 143, 984-990.	2.7	211
355	Quality of life in the Canadian Implantable Defibrillator Study (CIDS). <i>American Heart Journal</i> , 2002, 144, 282-289.	2.7	264
356	Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery. <i>Circulation</i> , 2002, 106, 75-80.	1.6	442
357	Quality of life in the Canadian Implantable Defibrillator Study (CIDS). <i>American Heart Journal</i> , 2002, 144, 282-289.	2.7	284
358	Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. <i>Journal of the American College of Cardiology</i> , 2001, 38, 167-172.	2.8	201
359	Circadian variation of paroxysmal atrial fibrillation. <i>American Journal of Cardiology</i> , 2001, 87, 794-798.	1.6	28
360	Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. <i>American Journal of Cardiology</i> , 2001, 88, 974-979.	1.6	83

#	ARTICLE	IF	CITATIONS
361	Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes. <i>Circulation</i> , 2001, 103, 3081-3085.	1.6	102
362	New-Onset Atrial Fibrillation. <i>Circulation</i> , 2001, 103, 2365-2370.	1.6	344
363	Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2001, 104, 1622-1626.	1.6	59
364	Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2001, 103, 1416-1421.	1.6	109
365	Trials of Physiologic Pacing. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000, 4, 156-158.	1.0	0
366	Canadian Implantable Defibrillator Study (CIDS). <i>Circulation</i> , 2000, 101, 1297-1302.	1.6	1,455
367	Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes. <i>New England Journal of Medicine</i> , 2000, 342, 1385-1391.	27.0	704
368	Randomized Crossover Comparison of DDDR Versus VDD Pacing After Atrioventricular Junction Ablation for Prevention of Atrial Fibrillation. <i>Circulation</i> , 2000, 102, 736-741.	1.6	117
369	Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. <i>American Heart Journal</i> , 2000, 139, 752-760.	2.7	13
370	The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Study protocol. <i>American Heart Journal</i> , 2000, 140, 735-739.	2.7	59
371	CLINICAL TRIALS OF PACING MODE SELECTION. <i>Cardiology Clinics</i> , 2000, 18, 1-23.	2.2	21
372	Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. <i>Journal of the American College of Cardiology</i> , 2000, 36, 794-802.	2.8	106
373	Amiodarone Interaction With β -Blockers. <i>Circulation</i> , 1999, 99, 2268-2275.	1.6	240
374	Evidence-Based Analysis of Amiodarone Efficacy and Safety. <i>Circulation</i> , 1999, 100, 2025-2034.	1.6	291
375	Atrial Pacing Periablation for Prevention of Paroxysmal Atrial Fibrillation. <i>Circulation</i> , 1999, 99, 2553-2558.	1.6	170
376	Appropriate Use of the Implantable Cardioverter Defibrillator: A Canadian Perspective. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 1-4.	1.2	4
377	Meta-analysis of antiarrhythmic drug trials. <i>American Journal of Cardiology</i> , 1999, 84, 90-93.	1.6	53
378	Evolving Indications for Permanent Pacing in Patients with Vasovagal Syncope. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998, 2, 52-53.	1.0	0

#	ARTICLE	IF	CITATIONS
379	The canadian registry of atrial fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. <i>American Journal of Cardiology</i> , 1998, 82, 82N-85N.	1.6	66
380	The Problem of Asymptomatic Ventricular Arrhythmias Among Survivors of Acute Myocardial Infarction: Role of Amiodarone. <i>ACC Current Journal Review</i> , 1998, 7, 12-14.	0.1	0
381	Implantable cardioverter defibrillators— for whom?. <i>Lancet, The</i> , 1998, 352, 338-340.	13.7	7
382	Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. <i>Lancet, The</i> , 1997, 349, 675-682.	13.7	915
383	North American Vasovagal Pacemaker Study: Study Design and Organization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997, 20, 844-848.	1.2	17
384	Dual-Chamber Versus Ventricular Pacing. <i>Circulation</i> , 1996, 94, 578-583.	1.6	117
385	The problem of asymptomatic ventricular arrhythmias among survivors of acute myocardial infarction: Role of amiodarone. <i>ACC Current Journal Review</i> , 1995, 4, 32-34.	0.1	3
386	"An AVID Dissent": Commentary. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1712-1713.	1.2	13
387	Standardized Reporting of ICD Patient Outcome: The Report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993, 16, 1358-1362.	1.2	82
388	Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): Rationale and protocol. <i>American Journal of Cardiology</i> , 1993, 72, F87-F94.	1.6	32
389	Canadian Implantable Defibrillator Study (CIDS): Study design and organization. <i>American Journal of Cardiology</i> , 1993, 72, F103-F108.	1.6	142
390	Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: The need for randomized trials. <i>American Journal of Cardiology</i> , 1992, 69, 959-962.	1.6	78
391	Canadian atrial fibrillation anticoagulation (CAFA) study. <i>Journal of the American College of Cardiology</i> , 1991, 18, 349-355.	2.8	1,128
392	Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. <i>American Journal of Cardiology</i> , 1989, 63, 817-819.	1.6	75
393	Concentration response relationships of amiodarone and desethylamiodarone. <i>American Heart Journal</i> , 1988, 115, 1208-1213.	2.7	18
394	Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. <i>Journal of the American College of Cardiology</i> , 1987, 10, 1145-1148.	2.8	59
395	Diltiazem and Propranolol, Alone and in Combination, on Exercise Performance and Left Ventricular Function in Patients with Stable Effort Angina: A Double-blind, Randomized, and Placebo-controlled Study. <i>Acta Pharmacologica Et Toxicologica</i> , 1985, 57, 55-60.	0.0	12
396	Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. <i>American Journal of Cardiology</i> , 1983, 52, 490-494.	1.6	838

#	ARTICLE	IF	CITATIONS
397	Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. American Journal of Cardiology, 1983, 52, 1208-1213.	1.6	93
398	Clinical Pharmacokinetics of N-acetylprocainamide. Clinical Pharmacokinetics, 1982, 7, 206-220.	3.5	37